CC-220

Closeout Clinical Study Report for Study CC-220-NHL-001

SYNOPTIC REPORT

A PHASE 1/2, MULTICENTER, OPEN-LABEL STUDY TO ASSESS SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF CC-220, ALONE AND IN COMBINATION WITH AN ANTI-CD20 MONOCLONAL ANTIBODY (MAB) IN SUBJECTS WITH RELAPSED OR REFRACTORY LYMPHOMAS

Indication:	Relapsed/refractory lymphomas
Phase:	1/2
Study Initiation Date:	11-Nov-2020
Study Completion Date:	30-Apr-2024
Report Date:	22-Aug-2024
Document Control Number:	930227957
Previous Version(s) of this Report:	Primary CSR dated 15-Dec-2023 DCN 930215415

THIS STUDY WAS CONDUCTED IN ACCORDANCE WITH GOOD CLINICAL PRACTICE

Sponsor's Responsible Medical Officer:
[redacted]
Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton, NJ 08543
United States of America

SYNOPSIS

Closeout Clinical Study Report for Study CC-220-NHL-001

TITLE OF STUDY: A Phase 1/2, Multicenter, Open-Label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (MAB) in Subjects With Relapsed or Refractory Lymphomas

PURPOSE: This was a Phase 1/2, multicenter, open-label study designed to evaluate CC-220 alone and in combination with an anti-CD20 mAb (rituximab or obinutuzumab) in study subjects with relapsed or refractory (R/R) lymphoma.

Patients with R/R lymphoma have insufficient therapeutic opportunities. Therefore, addition of a novel agent in the available options for these patients is of interest to improve therapeutic outcomes.

Iberdomide (BMS-986382; CC-17220/CC-220) is a high-affinity cereblon (CRBN)-modulating agent with anti-neoplastic and immunomodulatory properties that binds to the cullin ring ligase 4-CRBN E3 ubiquitin ligase complex,[1] promoting ubiquitination and proteasomal degradation of the hemopoietic transcription factors Ikaros and Aiolos.[2] Iberdomide demonstrates a range of immunomodulatory and antiproliferative activities. It has multiple effects on cells of the immune system, including immune cells of tumor microenvironment, B cells, and T cells, as well as nonimmune cell types, such as fibroblasts and endothelial cells. CC-220 has immunomodulatory activity on both lymphoid and myeloid cells and demonstrates antifibrotic activity. Moreover, CC-220 has antiproliferative activity on various lymphoma cell lines, including both ABC- and GCB-diffuse large B-cell lymphoma (DLBCL) cell lines.

CC-220 shares a similar mechanism of action with lenalidomide but compared to lenalidomide, has increased potency, both in terms of immunomodulatory and antiproliferative activities, and unique pharmacokinetic (PK) properties. Based on these properties, CC-220 is expected to show improved efficacy and tolerability in the treatment of lymphoma.

[redacted] A primary clinical study report (CSR) reported safety and efficacy results for primary and secondary objectives, as well as PK data based on a cutoff date of 28-Mar-2023 when the last enrolled subject had reached the first efficacy assessment. The purpose of this synoptic CSR is to report the follow-up results of the CC-220-NHL-001 study based on the 30-Apr-2024 cutoff date when the last enrolled subject completed study treatment and the 28-day safety follow-up visit. The clinical database was closed, but subjects are being followed for secondary primary malignancies (SPM) in the safety database. [redacted] This CSR includes safety and limited efficacy results collected from treated subjects for up to 16 months of follow-up from the date of the last subject first study drug dose administration date.

NUMBER OF SUBJECTS: Approximately 72 subjects (24 subjects in each cohort) were planned and 62 were enrolled in Part 1.

DISPOSITION, DEMOGRAPHICS, AND OTHER PERTINENT BASELINE CHARACTERISTICS:

Disposition

[redacted]

[redacted]

Demographics, Baseline Disease Characteristics, and Other Baseline Characteristics

Summaries of demographic characteristics, baseline disease characteristics, and other baseline characteristics (medical history and previous treatments) are presented in the primary CSR.